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Glutathionetransferaseenzymes(GSTs)catalyzereactionsinwhichelectrophilesareconjugatedtothetripeptidethiolglutathione.
While many GST-catalyzed transformations result in the detoxication of xenobiotics, a few substrates, such as dihaloalkanes,
undergo bioactivation to reactive intermediates. Many molecular epidemiological studies have tested associations between
polymorphisms (especially, deletions) of human GST genes and disease susceptibility or response to therapy. This review presents
a discussion of the biochemistry of GSTs, the sources—both genetic and environmental—of interindividual variation in GST
activities, and their implications for pharmaco- and toxicogenetics; particular attention is paid to the Theta class GSTs.
1.Introduction:Pharmacogenomicsand
PersonalizedMedicine:APerspective
The Golden Helix Symposium “Pharmacogenomics: paving
the path to personalized medicine,” held in Athens in
October 2009, brought together scientists and physicians
who share the hope and expectation that molecular analysis
of human genes aﬀecting pharmacodynamics and pharma-
cokinetics will soon lead to signiﬁcant medical advances.
Several kinds of improvements can be anticipated. For
example, starting drug doses may be tailored to an indi-
vidual’s metabolism, thereby increasing therapeutic eﬃcacy
and reducing side eﬀects; individuals for whom a particular
drug should be avoided altogether, to avert toxicity or
“idiosyncratic”reactions,mightbeidentiﬁedbypriorgenetic
screening; and mechanistic insights into the development of
particular diseases, drug side eﬀects, or toxicities resulting
fromenvironmentalexposuresmightbegarneredbyanalysis
of associations with speciﬁc genes [1, 2].
Our pursuit of this research agenda should be diligent
but also balanced. Despite optimistic predictions, well-
publicized in the popular press [3], clinical implementation
of genetically guided drug therapy has been slow. Both
fundamental and practical obstacles must be overcome
before the clinical potential of pharmacogenomics is realized
[4–6]. The goal of getting patients “the right drug in the
right dose” must be kept in perspective; for many people,
the urgent priority is to obtain any access at all to medical
care and to authentic prescription drugs [7]. This article
presents a review of the human glutathione transferases
(GSTs) and their genes, in the context of pharmacogenetics
and pharmacogenomics.
Manygenetic polymorphisms aﬀectingenzymes of xeno-
biotic metabolism strongly inﬂuence the pharmacokinetics
of clinically-important drugs (e.g., warfarin and P450 2C9
[8],6-mercaptopurineandthiopurinemethyltransferase[9],
irinotecan and UDP-glucuronosyltransferase 1A1 [10]). To
date, there are no such clear cases with respect to GSTs.
(The immunosuppressive drug azathioprine may prove to
be one instance [11, 12].) This paucity of examples is
certainly not due to a lack of genetic polymorphisms: GST
polymorphisms are common and some of them have clear
phenotypic consequences, as discussed below. Why, then,
do GST polymorphisms apparently have less impact on
pharmacokinetics? Several factors may be involved. First,
GSTs catalyze detoxication of electrophilic compounds by
conjugation to glutathione. Candidate drugs which give rise
to substantial amounts of electrophilic reactive species at2 Human Genomics and Proteomics
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Figure 1: Selected electrophilic substrates of GST enzymes. Top row, from left: acrolein; acrylamide; vinyl chloride (bioactivated to the
reactive intermediates 2-chloroethylene oxide and chloroacetaldehyde); bottom row, from left: trans-stilbene oxide (TSO); 1-chloro-2,4-
dinitrobenzene (CDNB); cumene hydroperoxide.
clinically eﬀective doses are likely to be too toxic for use—
the exception being cancer chemotherapeutic drugs [13–
15], where electrophilic reactivity can be the mechanism
of therapeutic action. Second, as discussed below, humans
express a large number of diﬀerent GSTs with overlapping
substrate speciﬁcities, and the eﬀects of polymorphisms
(including gene deletions) aﬀecting one GST may be masked
by the activity of others. Third, in some cases where
inactivation of a toxic drug metabolite by glutathione is
critical for prevention of toxicity, such as the quinoneimine
metabolite of acetaminophen, the nonenzymatic reaction
may be fast enough that variations in enzyme activity are
of little signiﬁcance [16]. Fourth, genetic polymorphisms
probably account for only a small proportion of the large
interindividual variation in GST expression and activity [17–
19] .F a c t o r ss u c ha sd i e t[ 20, 21], environmental chemical
exposures [22],age[23],andgender[24],whichremainonly
poorly understood, may be more important determinants.
Nevertheless, our understanding of human GST polymor-
phisms is still limited, and clinical consequences may simply
have gone unnoticed to date.
2. Glutathione Transferase Enzymes
2.1. Overview. Glutathione transferases (GSTs; systemati-
cally designated as “RX: glutathione R-transferases”, E.C.
2.5.1.18) are enzymes belonging to two protein superfami-
lies, the soluble GSTs and the “MAPEG” (Membrane Asso-
ciated Proteins in Eicosanoid and Glutathione metabolism)
proteins [5]. Soluble GSTs are dimers of 25kDa subunits.
Consequently, the homodimeric protein product of the
GSTA1 gene, for example, is referred to as GST A1-1. Crystal
structures have been determined for many soluble GSTs,
often with bound substrates or products. The “canonical
fold” of a soluble GST subunit reveals an N-terminal
α/β domain forming the GSH-binding site (“G-site”) and
a second, α-helical domain forming most of the “H-site” that
binds the electrophilic substrate.
Isaiah Berlin classiﬁed philosophers as either “foxes” or
“hedgehogs”, based on the classical Greek aphorism “The
fox knows many things, but the hedgehog knows one great
thing” [25]. Enzymes are commonly regarded as “hedge-
hogs”:eachenzymeonlyknowshowtocatalyzeonereaction.
However, the enzymes of xenobiotic metabolism, such as
P450 enzymes and GSTs, are undoubtedly “foxes” and able
to catalyze the biotransformation of numerous substrates
bearing diverse functional groups. As our understanding of
these enzymes has increased, so has the range of known
substrates and chemistries. Furthermore, the distinction that
was once drawn between enzymes catalyzing xenobiotic
metabolism and enzymes catalyzing metabolism of endoge-
nous substrates has largely disappeared. Major chemical
classes of GST substrates, such as quinones, epoxides, and
hydroperoxides, encompass both exogenous and endoge-
nous compounds. For example, acrolein (see Figure 1), a
toxic α,β-unsaturated aldehyde that occurs in cooked foods
and tobacco smoke [26–28] and is a metabolite of the
cancer chemotherapeutic drug cyclophosphamide [29], is
alsoformedendogenously,bythemyeloperoxidase-catalyzed
oxidationofthreonine[30];GSTscatalyzethedetoxicationof
hydroperoxides (glutathione peroxidase activity), including
both endogenous (e.g., hydrogen peroxide, lipid hydroper-
oxides) and exogenous (e.g., cumene hydroperoxide) com-
pounds [31, 32].
Overwhelmingly,themetabolicroleofGSTsistodetoxify
reactive electrophiles by catalyzing their reactions with
glutathione, thereby reducing the likelihood of deleterious
interactions between such reactive species and essential
cellular components, especially proteins and nucleic acids.
Manycancerchemotherapeuticagentsareelectrophiliccom-
pounds (or their metabolic precursors) and GST-catalyzed
reactions are important pathways for the inactivation andHuman Genomics and Proteomics 3
eliminationofmanysuchdrugs(e.g.,1,3-bis(2-chloroethyl)-
1-nitrosourea [33], cyclophosphamide, melphalan [34],
etc.). Drugs from other therapeutic classes may be metab-
olized to electrophiles that are substrates for GST-catalyzed
glutathione conjugation, for example, the phenylpropenal
metabolite of the epilepsy drug felbamate [35]. Many other
widely used drugs, including acetaminophen, clozapine, and
furosemide, are metabolized to glutathione conjugates [36],
although the reaction with glutathione is not necessarily
dependent on GST catalysis in every case. Glutathione
adducts are usually exported from the cell by the action
of transporters such as the multidrug resistance protein
MRP1 [37] and then processed into mercapturic acids (N-
acetylcysteine conjugates) which are excreted in the urine
[38]o rb ile[39].Despitetheimportant roleofglutathionein
detoxication, GST-catalyzed conjugations can also, in certain
instances, lead to the generation of reactive intermediates.
Dihaloalkanes are a notable case [40] and will be mentioned
again, later in this article.
2.2. Human GSTs. Human GST enzymes include members
of eight classes, assigned on the basis of sequence similarity:
Alpha,Mu,Pi,Theta,Kappa,Zeta,Omega,andSigma.Mam-
malian GSTs of the Alpha, Mu, and Pi classes bind with high
aﬃnity to matrices such as S-hexylglutathione-sepharose
or S-hexylglutathione-agarose [41, 42], but GST enzymes
from other classes, such as Theta, bind poorly or not at all
[43].(GST-GSHbindingaﬃnityisexploitedincommercially
available systems for expression of recombinant proteins as
GST fusions, such as the pGEX vectors.) Because of their
relatively high levels of expression and ease of puriﬁcation,
the Alpha, Mu, and Pi class GSTs have been studied more
frequently than other classes of human GST enzymes.
The speciﬁcities of GST enzymes for the electrophilic
substrate overlap considerably. For example, 1-chloro-2, 4-
dinitrobenzene (CDNB), commonly used for spectrophoto-
metric GST activity assays, is a substrate for most human
GSTs (but not GST T1-1 [44] or GST T2-2 [45]). On
the other hand, some substrates are relatively speciﬁc for
particular GST enzymes, as discussed later.
Further discussion of the biochemistry of GSTs is
presented in the monographs “Gluthione Transferases and
Gamma-Glutamyl Transpeptidases” [46] and “Toxicology
of Glutathione Transferases” [47] ,a n di nr e v i e wa r t i c l e s
[48–51].
3. GSTGenes
3.1. Overview. Both animal and plant genomes encode large
numbers of GST enzymes (and often, multiple pseudogenes
with strong sequence similarity to GST genes), for example,
48 GST genes in the nematode Caenorhabditis elegans [52],
26 in the mosquito Aedes aegypti [53], and more than 70
in the Black Cottonwood poplar Populus trichocarpa [54].
The human genome encodes at least 18 expressed GST
enzymes, in the eight sequence-similarity classes listed in
Section 2.2 [5, 51, 55, 56]. Among these, the Alpha, Mu,
Pi, and Theta classes have received most attention with
respect to drug metabolism in humans. Some ambiguity
persists in the enumeration of human GSTs. For example,
theAlpha-classhGSTA5geneproducthasbeenomittedfrom
tabulations of human GSTs, because its expression has never
been detected in human cells. However, the coding sequence
is intact and an enzymatically active recombinant protein
can be expressed; so it is likely that the enzyme is indeed
expressed in humans, albeit under conditions that have not
yet been discovered [57].
3.2. Human GST Gene Organization: Copy Number Varia-
tions. Human GST classes Alpha, Mu, Theta, and Omega
all have multiple members, encoded by clusters of paral-
ogous genes on a given chromosome (Figure 2). Deletion
polymorphismsofthegenesencodinghumanGSTM1-1and
GST T1-1 are common in the human population [58]. A
comprehensive review of the signiﬁcance of these polymor-
phisms in pharmacology and toxicology was published in
2006 [59]. These deletions presumably arose by homologous
recombination events. In both cases, although at least one
of the neighbouring GST genes remains intact, individuals
homozygous for the null allele show a clear phenotype with
respect to glutathione conjugation of speciﬁc substrates.
Homozygous deletion of the GSTM1 gene eliminates GST
activity with respect to conjugation of the characteristic GST
M1-1 substrate trans-stilbene oxide (TSO), as measured in
lymphocyte homogenates [60–62]; indeed, the phenotypic
polymorphism was discovered (with the substrate trans-
4-phenyl-3-buten-2-one) before the gene was cloned [63,
64]. Similarly, homozygous deletion of the GSTT1 gene
eliminates GST activity with respect to conjugation of the
characteristic GST T1-1 substrates methyl bromide (CH3Br)
and dichloromethane (CH2Cl2), as measured in erythrocyte
homogenates [65, 66]. These biochemical phenotypes have
toxicological correlates. For example, genotoxicity of TSO
in cultured human lymphocytes (as measured by induction
of sister chromatid exchanges) is signiﬁcantly elevated in
GSTM1-null individuals [67], and, as discussed later, clinical
toxicity of methyl bromide may be strongly determined by
GSTT1 genotype.
Deletion polymorphisms are a speciﬁc case of copy-
number variation, and the recombination mechanisms that
cause deletions can also cause duplications. The extent and
signiﬁcance of gene copy number variation in the human
genome has only recently started to become clear, lagging
behind the cataloguing of several million human single
nucleotide polymorphisms (SNPs) [74]. Human P450 2D6,
forinstance,providesanimportantexampleofcopy-number
variation—both deletions and duplications—aﬀecting the
disposition of drugs, such as the tricyclic antidepressants and
tamoxifen [75–77]. The GSTM1 gene is duplicated in some
individuals, conferring a +/++ genotype and “ultrarapid”
metabolism of TSO [78, 79].
3.3. Molecular Epidemiology of GST Deletion Polymor-
phisms. The relationships between GST polymorphisms
and disease risk have been examined in a vast number
of molecular epidemiological studies, beginning around4 Human Genomics and Proteomics
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Figure 2: Organization of selected human GST gene clusters. “P” indicates a pseudogene (e.g., AP3). The GST classes shown are Alpha
(chromosome 6p12) [68, 69], Mu (chromosome 1p13) [45, 46], Theta (chromosome 22q11.2) [70, 71], and Omega (chromosome 10q24.3)
[72, 73]. (A reverse transcribed pseudogene of the Omega class, found on chromosome 3 [72], is not shown.) GST genes are shown as white
text on black background and pseudogenes are shown as black text on a grey background. The direction of each gene is indicated by the
arrow. The genes GSTM1, GSTT2B,a n dGSTT1, each of which is commonly deleted, are shaded white. Genes DDT and DDT-L, in the Theta
cluster, encode the enzyme D-dopachrome tautomerase. DDT-L is commonly deleted along with GSTT2B. The ﬁgure is not drawn to scale.
1990. While these studies are not pharmacogenetic per se,
they may be relevant to the more general question of
whether human GST polymorphisms inﬂuence responses
to xenobiotic compounds, since environmental exposures
contribute to the risk of speciﬁc cancers and other preva-
lent diseases. A PubMed search using the search string
“GST cancer risk” retrieved 599 references (Jan. 2010),
and many noncancer diseases have also been studied, for
example, Parkinson’s disease, Alzheimer’s disease, asthma,
coronary artery disease, and rheumatoid arthritis (reviewed
in [59]). The HuGE Navigator “searchable knowledge base
of genetic associations and human genome epidemiology”
(http://www.hugenavigator.net/) retrieved 1,027 publica-
tions in response to a search for gene symbol GSTT1.
Almost all of the molecular epidemiological studies of GSTs
have tested the eﬀects of some or all of three genotypes:
GSTM1-null, GSTT1-null, and the GSTP1 single-nucleotide
polymorphism that results in the coding sequence change
Ile105Val [80, 81].
Several circumstances account for the fact that GST
polymorphisms have been subject to so many epidemio-
logical analyses. First, the polymorphisms are easily tested.
For example, routine PCR analysis can classify individuals
as GSTT1 homozygous null versus GSTT1-present and
GSTM1 homozygous null versus GSTM1-present; see, for
example, [82].(Thelimitationsofsuchanalysisarediscussed
later.) Second, homozygous null individuals are common,
contributing statistical power to molecular epidemiologi-
cal analyses. The prevalence of GSTM1 homozygous null
individuals in “Caucasian” and Asian populations is about
50%, with a substantially lower frequency among Africans
and African Americans. For the GSTT1 homozygous null
genotype, the corresponding ﬁgures are about 20% for
“Caucasian” and African-American populations, but about
50% for Asians [59]. Third, as mentioned earlier, the
polymorphisms give rise to detectable phenotypes, in terms
of metabolism of some speciﬁc substrates. Finally, the
acknowledged importance of GSTs in the disposition of
toxic compounds and in defense against oxidative stress [83]
provides a prima facie justiﬁcation for testing associations
with the risk of cancers and degenerative diseases.
Bolt and Thier have provided an extensive review of
the GST molecular epidemiology literature up to about
2005 [59]. Since that time, several new meta-analyses have
been published under the auspices of the “HuGE” Human
Genome Epidemiology Network, formed in 1998, which
facilitates the preparation of “systematic, structured, peer-
reviewed synopses of epidemiologic aspects of human genes
in relation to speciﬁc diseases” [84]. A summary of these
meta-analyses is given in Table 1.O v e r a l l ,i tc a nb es e e n
that GSTT1 or GSTM1 null genotype confers at most a
small (less than 50%) increased risk of certain cancers, while
many other results are negative (no statistically signiﬁcant
increased risk).Human Genomics and Proteomics 5
Table 1: HuGE reviews of GST polymorphisms and disease risk.
Disease Alleles Result Ref. Year
Bladder ca. M null ↑ 1.42 (1.26–1.60) [85] 2002
Ovarian ca. M, P, T negative [86] 2002
Lung ca. T Caucasians: negative Asians: null ↑ 1.28 (1.10–1.48) [87] 2006
Lung ca. M null ↑ 1.22 (1.14–1.30); negative when analysis was limited to the ﬁve largest studies [88] 2008
Liver ca. M, T T null possibly ↑ 1.19 (0.99–1.44); M null ↑ 1.16 (0.89–1.53) [89] 2008
Lung ca. P (V/V + V/I) versus (I/I) ↑ 1.11 (1.03–1.21) [90] 2009
Prostate ca. M, P, T M: 1.33 (1.15–1.55); P and T negative [91] 2009
Colorectal ca. P negative [92] 2009
Colorectal ca. T null ↑ 1.23 (1.02–1.49) [93] 2010
Asthma M, P, T negative [94] 2010
M: GSTM1 null; T: GSTT1 null; P: GSTP1 I105V SNP; ↑: increased risk for individuals with the speciﬁed genotype; Results: numbers represent Odds Ratios,
with 95% conﬁdence intervals in parentheses; ca.: cancer.
The great majority of the molecular epidemiological
investigations published to date suﬀer from a serious lim-
itation: genotypes were assessed by “yes-no” PCR methods
that do not measure gene copy number and therefore cannot
distinguish between heterozygous (+/0) and homozygous
(+/+orev en++/+)non-nullgenotypes.AsnotedbyMinelli
et al. [94], “classifying the genotype [only] as “present” or
“null” implies a recessive model (one or two copies versus
absence of the risk allele), which may not reﬂect the true
underlying genetic model and thus may not provide a valid
and accurate estimate of the genetic risk. GSTT1 or GSTM1
copy number variations are correlated with altered enzyme
activity, and analysis in a dose-dependent manner would
best describe any disease outcome association. ” Analytical
methods that assess copy number, such as real-time PCR
[95–97], are now available; older and less informative
genotyping methods should be abandoned [98].
Several other biases and weaknesses are often found in
molecular epidemiological investigations and tend to reduce
conﬁdence in published results. (i) Post hoc analysis: data can
be recategorized so as to increase statistical signiﬁcance, by
constructing a new hypothesis after the data have already
been acquired. For example, in a study of the GSTM1 null
polymorphism and ovarian cancer risk [99], very high sta-
tistical signiﬁcance was reported for elevated risk of GSTM1
null genotype with respect to the incidence of combined
clear cell and endometrioid pathological subtypes of ovarian
cancer, but this combination of subtypes was constructed
post hoc, and the biological rationale explaining why these
subtypes in particular should be aﬀected by GSTM1 status
is not compelling. (ii) Publication bias: studies which ﬁnd
signiﬁcant associations are more likely to be published than
studies which ﬁnd no association. The recent HuGE meta-
analysis of asthma studies [94] noted “clear absence of small
studies with negative results, suggesting the presence of
publication bias.” (iii) Small sample size: published studies
of the GSTT1 and GSTM1 polymorphisms include samples
as small as 34 patients with chronic obstructive pulmonary
disease [100], 51 liver transplant recipients [101], and 43
schizophrenia patients [102], and such small samples are
unlikely to yield reliable data. (iv) Lack of clear biological
rationale: is it reasonable to expect that the presence of
a non-null GSTT1 gene is associated with, for example,
signiﬁcantly better response to the surgical correction of an
enlarged scrotal vein [103]? In contrast, an epidemiological
association is more credible when a plausible connection
exists between a presumed causative agent and the dis-
ease outcome. A strong association between GSTM1 null
genotype and hepatocellular carcinoma has been reported
in studies in Guangxi, China [104, 105]. The very high
incidenceoflivercancerinthisregionisattributed,atleastin
part, to prevalent aﬂatoxin contamination of grain, and GST
M1-1 catalyzes the detoxication of aﬂatoxin epoxide [106].
4. HumanGSTTheta GenesandEnzymes
4.1. Characteristics of Theta Class GSTs. Theta class GSTs are
distinct from the Alpha, Mu, and Pi (A-M-P) class enzymes
in many respects, including sequence, catalytic activity, and
structure [107]. GST Theta genes are evolutionarily very
distant from the A-M-P genes and probably diverged from
theancestralA-M-Pgenelongbeforethedivergenceofplants
and animals; Theta class GSTs are found in plants, but A-M-
P GSTs are absent [108] .T h eh u m a ng e n o m ee n c o d e st w o
Theta class GSTs, GST T1-1 and GST T2-2 [70], and possibly
a third form, GST T2B-2B (see below). Three Theta class
GSTs are encoded on the mouse genome [109].
As noted earlier, Theta class enzymes are distinct from
the A-M-P enzymes in failing to bind tightly to glutathione
aﬃnity matrices and having little or no activity with the
standard GST substrate CDNB [110]. Theta class GSTs
have a distinctive (although not unique [111]) activity:
catalysis of the conjugation of halo- and dihaloalkanes with
glutathione[40],areactionwhichcanresultintheformation
of reactive intermediates related to the “sulfur mustards” (S-
haloalkanes) [112]. Therefore, Theta class GSTs can catalyze
bioactivation [113] as well as detoxication processes, as
discussed further below. An intriguing case report [114]
suggests that GST T1-1-dependent activation of haloalkanes
can be clinically important. Two workers were exposed to
a very large inhaled dose of methyl bromide when they6 Human Genomics and Proteomics
GSTTP2 GSTT1 GSTTP1
DDT
DDT-L GSTT2
GSTT2B
24400K 24350K 24300K
Figure 3: Organization of the human GST Theta gene region. The
ﬁgure is drawn approximately to scale, based on NCBI Reference
Sequence: NC 000022.10, Homo sapiens chromosome 22, GRCh37
primary reference assembly.
entered a sealed mill building being fumigated with the
gas, and failed to wear self-contained breathing apparatus.
Neurotoxic eﬀectswere very severe in one worker but mild in
the other. Laboratory investigation showed that the severely
aﬀected individual had GST (presumably GST T1-1) activity
towardsmethylbromide,whilethemildlyaﬀectedindividual
(presumablyaGSTT1homozygousnull)didnot.Thisresult,
while representing little more than an anecdotal report, is
consistent with a determinative role for GST T1-1 in methyl
bromide toxicity.
The active sites of Theta class GSTs are also distinctive.
In A-M-P class GSTs, a conserved tyrosine residue near the
N-terminus forms a hydrogen bond to the thiol sulfur atom
of glutathione in the G-site; in Theta class GSTs, a serine
residue occupies the corresponding position [48, 115–117].
T h eG - s i t eo fh u m a nT h e t ac l a s sG S T si sd e e p l yb u r i e d
and covered by the C-terminal “tail”, approximately 40
amino acid residues that form a helix-loop-helix extension
[116]; this tail also makes the H-site of Theta class enzymes
relatively inaccessible [118]. The small size of the H-site is
consistent with the selectivity of Theta class GSTs for small
xenobiotic substrates, such as dichloromethane [119]. This
preference for small xenobiotic substrates is reminiscent of
the behaviour of cytochrome P450 2E1, an enzyme which
is also notable for an unusually small active site [120], and
which catalyzes the oxidation of small substrates such as
dimethylnitrosamine [121] and ethanol [122]. Indeed, there
may be cases where toxicants are activated by P450 2E1
to reactive species that are subsequently detoxiﬁed by GST
T1-1-catalyzed glutathione conjugation. Possible examples
include vinyl chloride (a plastics monomer and industrial
carcinogen) [123, 124], acrylamide [125], and benzene [126,
127].
4.2. Chromosomal Organization of the GSTT Genes. The
structure of the human GST Theta region [70, 71]i s
remarkable (Figure 3). The GST1 and GST2 are oriented
head-to-head. GSTT2B w a so r i g i n a l l yr e f e r r e dt oa sa
probable pseudogene, GSTT2P [70], but is now annotated
as “glutathione S-transferase theta 2B (gene/pseudogene)”
on the NCBI genome database. (Pseudogenes identiﬁed as
GSTTP1 and GSTTP2 are also annotated on the database but
have not been studied in detail.) The GSTT2, DDT, DDT-
L,a n dGSTT2B genes are found within a 61kb inverted
repeat sequence which was recently discovered to be the
site of a prevalent (allele frequency approximately 50%)
deletion polymorphism that spans the entire GSTT2B gene
[71]. Additional characteristics of this previously unknown
deletion polymorphism may have important implications
for pharmacogenetic studies of the GST Theta genes. Sur-
prisingly, deletion of the GSTT2B gene appears to result in
greatly reduced expression of the GSTT2 gene, by an as-
yet unknown mechanism; the GSTT2B deletion shows link-
age disequilibrium with the much-studied GSTT1 deletion
polymorphism, with a very low frequency of alleles carrying
deletions of both GSTT1 and GSTT2B [71]. Furthermore,
the extent of linkage disequilibrium was very diﬀerent
among three population samples examined: very strong in
a northern/western European ancestry sample, strong in a
Japanese-Chinese sample, but absent in a Nigerian Yoruba
sample [71]. Further investigation of the molecular genetics
of human GSTs is very much needed.
4.3. D-Dopachrome Tautomerase. Another intriguing feature
of the GST Theta gene region is the presence within
the 61kb inverted repeat of the overlapping, head-to-
head DDT (D-dopachrome tautomerase) and DDT-L (D-
dopachrome tautomerase-like)coding sequences.As Coggan
et al. observed, the proximity of the DDT and GSTT2
genes is “if nothing else, an interesting coincidence.” Does
the proximity of these genes have any functional sig-
niﬁcance? First, we should consider the biochemistry of
the DDT gene product, D-dopachrome tautomerase. L-
Dopachrome is a tyrosine metabolite required for biosyn-
thesis of the skin pigment melanin [128]. Hydroxylation
of tyrosine forms dopa (dihydroxyphenylalanine), which
is oxidized to the quinone, dopaquinone (Figure 4); both
oxidations are catalyzed by tyrosinase [129]. Dopaquinone
can cyclize to give cyclodopa, which undergoes further
oxidation to yield dopachrome [130]. In the pathway to
eumelanin, L-dopachrome tautomerase (also known as
L-dopachrome isomerase) catalyses the isomerization of
dopachrome,viaatautomericform(dopachrometautomer),
to 5,6-dihydroxyindole-2-carboxylic acid [131]. (Alterna-
tively, dopaquinone can react with cysteine to form cys-
teinyldopa, leading to synthesis of phaeomelanin [130].)
All of these metabolites are derived from the natural “L”
enantiomer of the amino acid tyrosine. In the course of
studies on L-dopachrome tautomerase, researchers used the
nonnatural “D” enantiomer of dopachrome as a control;
to their surprise, they found that D-dopachrome also
underwent tautomerization. Liver (rather than melanin-
producing cells) was found to have high D-dopachrome tau-
tomerase activity [132]. D-Dopachrome tautomerase (also
known as D-dopachrome decarboxylase) catalyzesthe decar-
boxylation of D-dopachrome to give 5,6-dihydroxyindole
[133]. The cytokine macrophage migration inhibitory factor
(MIF) [134], another member of the tautomerase super-
family [135], catalyzes the conversion of D-dopachrome
into 5,6-dihydroxyindole-2-carboxylic acid [136]. Since D-
dopachrome is not found in cells, these enzymes presum-
ably have diﬀerent endogenous substrates, possibly includ-
ing phenylpyruvate [137]. The physiological role of D-
dopachrome tautomerase remains enigmatic.Human Genomics and Proteomics 7
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Figure 4: Dopamine and some of its oxidized metabolites relevant to the biosynthesis of melanin.
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Figure 5: Activation of ethylene dibromide to an electrophile by glutathione conjugation.
There are at least some hints of a functional relation-
ship between D-dopachrome tautomerase and GSTs. (i)
Dopachrome and related quinones are substrates for GST-
catalyzed glutathione conjugation [138, 139]. (ii) The DDT
and GSTT2 genes may be coordinately regulated; a recent
genomewide analysis identiﬁed both genes among a small
set of genes that are expressed diﬀerentially in a comparison
between strains of spontaneously hypertensive rats and the
control (Wistar-Kyoto) strain [140]. (iii) A recent proteomic
analysis identiﬁed D-dopachrome tautomerase as being
strongly (more than tenfold) induced in rat liver following
exposure to the hepatotoxicant, carbon tetrachloride (CCl4)
[141] ,a n dG S Te n z y m e sm a yp r o t e c ta g a i n s tC C l 4-induced
hepatotoxicity [142]. Further research is needed to clarify
the biological role of D-dopachrome tautomerase and its
possible interactions with the glutathione/GST system.
4.4. Bioactivation of Mutagens by Theta Class GSTs. As men-
tioned earlier, GST-catalyzed conjugation of dihaloalkanes
gives rise to toxic reactive intermediates. Ethylene dibromide
(EDB), a compound that has been used as an antiknock
additive in gasoline and as an insecticide, can cause fatal
liver, kidney, and cardiac toxicity [143]. EDB is probably the
best-characterized example of GST-catalyzed bioactivation
[144, 145]. EDB-glutathione conjugation catalyzed by GST
T1-1 leads to generation of an electrophilic sulphonium ion
that can form covalent adducts with macromolecular targets
[146](Figure 5).Itwouldbeveryinformativetotestwhether
GSTT1 genotype aﬀects the outcome of EDB poisonings in
exposed individuals (suchas accidental poisonings or suicide
attempts).
Mammalian enzymes catalyzing the metabolic activation
of xenobiotics can be expressed in bacterial strains for the
detection of mutagens [147], as has been demonstrated for
aromatic amine N-acetyltransferases [148], P450 enzymes
[149], and sulfotransferases [150]. Thier and colleagues
demonstrated that rat GST T1-1 (previously known as
form 5-5) [151] and human GST T1-1 [152] expressed in
Salmonella typhimurium strains catalyze the bioactivation of
dihaloalkanestomutagensthatcanreadilybedetectedbythe
Ames test (reversion mutation assay).
4.5. Coding-Sequence SNPs Aﬀecting GST Theta Proteins.
With the exception of the GSTP1 SNP mentioned earlier,8 Human Genomics and Proteomics
there have been relatively few studies of coding-sequence
SNPs aﬀecting GST proteins. However, the Environmental
Genome Project [153] and several recent publications [154–
161] have uncovered many new variants in the Mu, Pi,
Theta, and Omega GST classes. Characterization of the
functional consequences of these variants is required for a
thorough understanding of the pharmacogenetics of GSTs
[162] and can also provide insight into the structure-activity
relationships of the enzyme proteins. The eﬀects of coding-
sequence SNPs aﬀecting the human Theta class GSTs are
under investigation [163, 164]. A GST expression system
based on Escherichia coli strains bearing a lacZ reversion tar-
gethasbeenconstructedandisbeingappliedinstudiesofthe
functional consequences of nonsynonymous SNPs in human
GSTT1 [164]. Reported nonsynonymous SNPs in this gene
(Entrez SNP database at NCBI; Environmental Genome
Project database at www.genome.utah.edu/genesnps/;[ 160])
encode the protein variants A21T, L30P, D43N, F45C, T65M,
R76S, T104P, D141N, V169I, and E173K. In our ﬁrst study,
we expressed the D141N and E173K variants. The D141N
variant behaved similarly to the wild-type enzyme, in terms
of expression level and speciﬁc activities towards a variety
of xenobiotic substrates. However, the variant displayed a
very much reduced activity for the activation of EDB to a
mutagen. Variant E173K, in contrast, was poorly expressed
and inactive with most substrates, and the protein appears
to be improperly folded, as judged by its altered thermal
denaturation proﬁle. Extension of these studies to additional
GSTT1 SNPs is in progress.
5. Closing Remarks
A large number of epidemiological studies have tested pos-
sible associations between GST polymorphisms, such as the
GSTM1 and GSTT1 deletions, with disease risk or therapy
outcome. Some meta-analyses have indicated statistically
signiﬁcant but small increases in risk for speciﬁc genotypes,
while many studies have been negative. However, the genetic
analysis used in most of these studies has been limited,
especially by the failure to determine between heterozygous
and homozygous genotypes (gene dose). GST activity is
highly variable among individuals, but genetic factors may
account for only a fraction of this variability. Although clear
cases of clinically relevant pharmacogenetic consequences
and toxicogenetic GST polymorphisms remain very few,
greater understanding of the numerous factors aﬀecting
GST expression and activity, accompanied by more incisive
genetic analysis, may reveal further connections between
GST genotypes and individual responses to drugs and toxic
compounds.
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